

Global Eyes Corporation  
1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei  
City, Taiwan

Report No. : AFA23305232M01

Date : 2023/04/12



**Product Name :** coffee Tabs  
**Sample Packaging :** Please refer to the photos for sample shown at the page of this report  
**Sample Condition/Amount :** Ambient temp./5 pieces  
**Item No. :** —  
**Lot. No. :** —  
**Applicant :** Global Eyes Corporation  
**Applicant address/  
telephone number/  
contact person :** 1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei City 241,  
Taiwan/02-22789928/蔡佳勳  
**Manufacturer/Vendor :** Gloabal Eyes Corporation  
**Manufacture Date :** —  
**Expiry Date :** —  
**Country of Origin :** TAIWAN

**The above sample information is provided and confirmed by the applicant.**

**Sample Received :** 2023/03/17  
**Testing Date :** 2023/03/17  
**Test Results:** -Please refer to next page(s)-

  
Gar Sung, Manager  
Signed for and on behalf of  
SGS Taiwan Ltd.



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

**Global Eyes Corporation**  
 1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei  
 City, Taiwan

Report No. : AFA23305232M01  
 Date : 2023/04/12



Test Item	Test Method	Results	LOQ/LOD (Note 3.)	Unit
Arsenic(As)	MOHW Food No. 1031901169 amended on 2014/08/25. General Method of Test for Heavy Metals.(MOHWH0014.03)	N.D.	2.0	mg/kg
Lead(Pb)		N.D.	2.0	mg/kg
Cadmium(Cd)		N.D.	2.0	mg/kg
Mercury(Hg)		N.D.	2.0	mg/kg
Copper(Cu)		N.D.	2.0	mg/kg
Aflatoxins	---	---	---	---
Aflatoxin B1	MOHW Food No. 1091901654 amended on 2020/09/02. Method of Test for Mycotoxins in Foods-Test of Aflatoxins.(MOHWT0001.04)(Note : Matrix of the announced method was extended, and it is not within the scope of TFDA certification.)	N.D.	0.2	µg/kg
Aflatoxin B2		N.D.	0.1	µg/kg
Aflatoxin G1		N.D.	0.2	µg/kg
Aflatoxin G2		N.D.	0.1	µg/kg

Note:

- The test report merely reflects the test results of the consigned matters of the client and is not a certification of the legitimacy of the related products.
- This testing report contains 27 pages and it's invalid when they are separated.
- If the testing item belongs to quantitative analysis then this column describes Limit of Quantification(LOQ); If the testing item belongs to qualitative analysis then this column describes Limit of Detection(LOD).
- Result reported as "N.D." or "Negative" denotes value lower than LOQ/LOD.
- All items in this testing report is based on the request from client and we are responsible for that.
- The test report(AFA23305232M01)Aflatoxin total : N.D. .
- Methyl Mercury / Inorganic Arsenic / Heavy Metals Testing Site: No.38, Wuquan 7th Road, New Taipei Industrial Park, Wu Ku District, New Taipei City 24886 , Taiwan. (R.O.C.)
- The report, AFA23305232M01, was reissued on 2023/04/12.

- END -

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Global Eyes Corporation  
1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei  
City, Taiwan

Report No. : AFA23305232M01  
Date : 2023/04/12



<u>Product Name :</u>	coffee Tabs
<u>Sample Packaging :</u>	Please refer to the photos for sample shown at the page of this report
<u>Sample Condition/Amount :</u>	Ambient temp./5 pieces
<u>Item No. :</u>	—
<u>Lot. No. :</u>	—
<u>Applicant :</u>	Global Eyes Corporation
<u>Applicant address/telephone number/contact person :</u>	1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei City 241, Taiwan/02-22789928/蔡佳勳
<u>Manufacturer/Vendor :</u>	Gloabal Eyes Corporation
<u>Manufacture Date :</u>	—
<u>Expiry Date :</u>	—
<u>Country of Origin :</u>	TAIWAN

**The above sample information is provided and confirmed by the applicant.**

<u>Sample Received :</u>	2023/03/17
<u>Testing Date :</u>	2023/03/17
<u>Test Requested:</u>	Determination of the pesticides
<u>Test Method1.</u>	MOHW Food No. 1111901537 amended on 2022/08/17. Method of Test for Pesticide Residues in Foods- Multiresidue Analysis (5).(MOHWP0055.05) (Note : Matrix of the announced method was extended.)
<u>Test Results :</u>	<b>The sample was tested for Determination of 410 pesticides, and the results were found to be not detected with those pesticides as listed.</b>

Note:

1. The test report merely reflects the test results of the consigned matters of the client and is not a certification of the legitimacy of the related products.
2. This testing report contains 27 pages and it's invalid when they are separated.
3. The result will be consolidated as above table if it is greater than detection limit. However, the result will be shown as "N.D.", when it's less than detection limit. The testing items and its detection limit are included in the appendix.
4. "\*" Indicates lower limit of analytical determination of announced test method. Please refer to the latest announcement if there is a test method revision.
5. All items in this testing report is based on the request from client and we are responsible for that.
6. Test method 1. is not applicable to the determination of Benfuracarb, Pymetrozine and Nitenpyram in samples like Class III (samples including dry tea, fruits and vegetables, spices and other herbs containing high amount of pigments).
7. The report, AFA23305232M01, was reissued on 2023/04/12.

- END -

*Gar Sung*  
Gar Sung, Manager  
Signed for and on behalf of  
SGS Taiwan Ltd.



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Appendix

Report No. : AFA23305232M01

Date : 2023/04/12



Test items & LOQ List :

Unit: ppm

No.	Test Item	LOQ	No.	Test Item	LOQ
1.	Abamectin	0.05	41.	Boscalid	0.05
2.	Acephate	0.05	42.	Bromacil	0.05
3.	Acequinocyl-hydroxyl	0.05	43.	Bromophos	0.05
4.	Acetamiprid	0.05	44.	Bromophos-ethyl	0.05
5.	Acetochlor	0.05	45.	Bromopropylate	0.05
6.	Acibenzolar-S-methyl	0.05	46.	Bromuconazole	0.05
7.	Acrinathrin	0.05	47.	Bufencarb	0.03
8.	Alachlor	0.05	48.	Bupirimate	0.05
9.	Alanycarb	0.05	49.	Buprofezin	0.05
10.	Aldicarb	0.02	50.	Butachlor	0.03
11.	Aldicarb sulfone	0.02	51.	Butafenacil	0.05
12.	Aldicarb sulfoxide	0.02	52.	Butocarboxim	0.05
13.	Aldrin	0.03	53.	Butralin	0.05
14.	Allethrin	0.1	54.	Butylate	0.05
15.	Alloxydim(sodium)	0.05	55.	Cadusafos	0.05
16.	Ametoctradin	0.05	56.	Carbaryl	0.05
17.	Ametryn	0.05	57.	Carbendazim	0.05
18.	Amisulbrom	0.05	58.	Carbofuran	0.05
19.	Atrazine	0.05	59.	3-keto Carbofuran	0.05
20.	Azafenidin	0.05	60.	3-OH Carbofuran	0.05
21.	Azinphos-methyl	0.1	61.	Carbophenothion	0.05
22.	Aziprotryne	0.05	62.	Carbosulfan	0.05
23.	Azoxystrobin	0.05	63.	Carfentrazone-ethyl	0.05
24.	Benalaxyl	0.05	64.	Carpropamid	0.05
25.	Bendiocarb	0.05	65.	Chinomethionat	0.05
26.	Benfluralin	0.05	66.	Chlorantraniliprole	0.03
27.	Benfuracarb	Note 6	67.	Chlorbenzuron	0.05
28.	Bensulfuron-methyl	0.05	68.	Chlorfenapyr	0.05
29.	Bentazone	0.05	69.	Chlorfenvinphos	0.05
30.	Benthiazole	0.05	70.	Chlorfluazuron	0.05
31.	Benzovindiflupyr	0.05	71.	Chlorobenzilate	0.05
32.	Benzoximate	0.05	72.	Chloropropylate	0.02
33.	α-BHC	0.03	73.	Chlorothalonil	0.05
34.	β-BHC	0.05	74.	Chlorpropham	0.05
35.	γ-BHC (Lindane)	0.05	75.	Chlorpyrifos	0.03
36.	δ-BHC	0.05	76.	Chlorpyrifos-methyl	0.05
37.	Bifenazate	0.05	77.	Chlorthal-dimethyl	0.05
38.	Bifenox	0.05	78.	Chlozolinate	0.05
39.	Bifenthrin	0.03	79.	Chromafenozide	0.05
40.	Bitertanol	0.05	80.	Cinosulfuron	0.05

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Appendix

Report No. : AFA23305232M01

Date : 2023/04/12



Test items & LOQ List :

Unit: ppm

No.	Test Item	LOQ	No.	Test Item	LOQ
81.	cis-Chlordane	0.05	121.	Dimethoate	0.05
82.	Clethodim	0.05	122.	Dimethomorph	0.05
83.	Clofentezine	0.05	123.	Diniconazole	0.05
84.	Clomazone	0.05	124.	Dinitramine	0.05
85.	Clomeprop	0.05	125.	Dinotefuran	0.05
86.	Clothianidin	0.03	126.	Diphenamid	0.05
87.	CPMC (Etrfol)	0.05	127.	Diphenylamine	0.05
88.	Cyanazine	0.05	128.	Disulfoton	0.05
89.	Cyanofenphos	0.05	129.	Ditalimfos	0.03
90.	Cyanophos	0.05	130.	Dithiopyr	0.05
91.	Cyantraniliprole	0.05	131.	Diuron	0.05
92.	Cyazofamid	0.05	132.	Dymron	0.05
93.	Cyclaniliprole	0.05	133.	Edifenphos	0.05
94.	Cyclosulfamuron	0.05	134.	Emamectin benzoate B1a	0.03
95.	Cycloxydim	0.05	135.	Emamectin benzoate B1b	
96.	Cyenopyrafen	0.05	136.	α-Endosulfan	0.05
97.	Cyflufenamid	0.05	137.	β-Endosulfan	0.05
98.	Cyflumetofen	0.05	138.	Endosulfan-sulfate	0.05
99.	Cyfluthrin	0.03	139.	Endrin	0.05
100.	Cyhalofop-butyl	0.05	140.	EPN	0.03
101.	λ-Cyhalothrin	0.03	141.	Epoxiconazole	0.05
102.	Cymoxanil	0.05	142.	Esfenvalerate	0.03
103.	Cypermethrin	0.03	143.	Ethion	0.05
104.	α-Cypermethrin	0.03	144.	Ethiprole	0.05
105.	Cyproconazole	0.05	145.	Ethirimol	0.05
106.	Cyprodinil	0.05	146.	Ethoprophos	0.05
107.	Deltamethrin	0.03	147.	Etofenprox	0.05
108.	Demeton-S-methyl	0.05	148.	Etoxazole	0.05
109.	Dialifos	0.05	149.	Etridiazole	0.05
110.	Diazinon	0.05	150.	Etrimfos	0.05
111.	Dichlorvos	0.05	151.	Famoxadone	0.05
112.	Dicloran	0.05	152.	Fenamiphos	0.05
113.	Dicofol&DCBP	0.05	153.	Fenarimol	0.05
114.	Dicrotophos	0.05	154.	Fenazaquin	0.05
115.	Dieldrin	0.05	155.	Fenbuconazole	0.05
116.	Difenoconazole	0.05	156.	Fenbutatin-oxide	0.05
117.	Diflubenzuron	0.05	157.	Fenchlorphos	0.25
118.	2,6-Diisopropyl-naphthalene(2,6-DIPN)	0.5	158.	Fenhexamid	0.05
119.	Dimethenamid	0.05	159.	Fenitrothion	0.05
120.	Dimethipin	0.05	160.	Fenobucarb	0.05

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Appendix

Report No. : AFA23305232M01

Date : 2023/04/12



Test items & LOQ List :

Unit: ppm

No.	Test Item	LOQ	No.	Test Item	LOQ
161.	Fenothiocarb	0.05	201.	Haloxypop-methyl	0.05
162.	Fenoxanil	0.05	202.	Heptachlor	0.05
163.	Fenoxaprop-ethyl	0.05	203.	Heptachlor epoxide	0.05
164.	Fenoxycarb	0.05	204.	Heptenophos	0.05
165.	Fenpropathrin	0.05	205.	Hexaconazole	0.05
166.	Fenpropimorph	0.05	206.	Hexaflumuron	0.05
167.	Fenpyrazamine	0.05	207.	Hexazinone	0.05
168.	Fenpyroximate	0.05	208.	Hexythiazox	0.05
169.	Fensulfothion	0.05	209.	Imazalil	0.05
170.	Fenthion	0.05	210.	Imibenconazole	0.1
171.	Fenvalerate	0.03	211.	Imicyafos	0.05
172.	Ferimzone	0.05	212.	Imidacloprid	0.05
173.	Fipronil	0.002	213.	Indoxacarb	0.01
174.	Fipronil-sulfone	0.002	214.	Iprobenfos	0.05
175.	Flazasulfuron	0.05	215.	Iprodione	0.05
176.	Flonicamid	0.05	216.	Iprovalicarb	0.05
177.	Florpyrauxifen-benzyl	0.05	217.	Isazofos	0.05
178.	Fluazifop-P-butyl	0.05	218.	Isafenphos	0.05
179.	Fluazinam	0.05	219.	Isfetamid	0.05
180.	Flubendiamide	0.05	220.	Isoprocarb	0.05
181.	Flucythrinate	0.05	221.	Isoprothiolane	0.05
182.	Fludioxonil	0.06	222.	Isopyrazam	0.05
183.	Fluensulfone	0.05	223.	Isotianil	0.05
184.	Flufenoxuron	0.05	224.	Isouron	0.05
185.	Fluopicolide	0.03	225.	Isoxaflutole	0.05
186.	Fluopyram	0.05	226.	Isoxathion	0.1
187.	Flupyradifurone	0.05	227.	Kresoxim-methyl	0.05
188.	Fluroxypyr-meptyl	0.05	228.	Leptophos	0.05
189.	Flusilazole	0.05	229.	Linuron	0.05
190.	Flutolanil	0.05	230.	Lufenuron	0.05
191.	Flutriafol	0.05	231.	Malathion	0.05
192.	Fluvalinate	0.05	232.	Mandipropamid	0.03
193.	Fluxapyroxad	0.03	233.	Mecarbam	0.05
194.	Fonofos	0.05	234.	Mefenacet	0.05
195.	Formetanate	0.05	235.	Mefentrifluconazole	0.05
196.	Formothion	0.05	236.	Mepanipyrim	0.05
197.	Fosthiazate	0.05	237.	Mephosfolan	0.05
198.	Fthalide	0.05	238.	Mepronil	0.05
199.	Furametpyr	0.05	239.	Metaflumizone	0.05
200.	Halfenprox	0.05	240.	MetalaxyI	0.05

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Appendix

Report No. : AFA23305232M01

Date : 2023/04/12



Test items & LOQ List :

Unit: ppm

No.	Test Item	LOQ	No.	Test Item	LOQ
241.	Metazachlor	0.05	281.	p,p'-DDE	0.02
242.	Metconazole	0.05	282.	p,p'-DDT	0.02
243.	Methacrifos	0.05	283.	Paclobutrazol	0.05
244.	Methamidophos	0.05	284.	Parathion	0.05
245.	Methidathion	0.05	285.	Parathion-methyl	0.05
246.	Methiocarb	0.05	286.	Penconazole	0.05
247.	Methomyl	0.05	287.	Pencycuron	0.05
248.	Methoprene	0.05	288.	Pendimethalin	0.05
249.	Methoxyfenozide	0.05	289.	Penflufen	0.05
250.	Methyl pentachlorophenyl sulfide	0.02	290.	Penoxsulam	0.05
251.	Metobromuron	0.05	291.	Pentachloroaniline	0.02
252.	Metolachlor	0.05	292.	Penthiopyrad	0.05
253.	Metolcarb	0.05	293.	Permethrin	0.05
254.	Metrafenone	0.05	294.	Phenothiol	0.05
255.	Metribuzin	0.05	295.	Phenothrin	0.05
256.	Mevinphos	0.05	296.	Phenthoate	0.05
257.	Milbemectin A3	0.05	297.	2-Phenylphenol	0.05
258.	Milbemectin A4		298.	Phorate	0.05
259.	Mirex	0.05	299.	Phosalone	0.05
260.	Molinate	0.05	300.	Phosmet	0.05
261.	Monocrotophos	0.05	301.	Phosphamidon	0.05
262.	MPMC (Xylylcarb)	0.05	302.	Phoxim	0.05
263.	Myclobutanil	0.05	303.	Pinoxaden	0.05
264.	Napropamide	0.05	304.	Piperonyl butoxide	0.05
265.	Nitenpyram	Note 6	305.	Pirimicarb	0.05
266.	Norflurazon	0.05	306.	Pirimiphos-ethyl	0.05
267.	Novaluron	0.05	307.	Pirimiphos-methyl	0.05
268.	Nuarimol	0.05	308.	Pretilachlor	0.05
269.	o,p'-DDD	0.02	309.	Probenazole	0.05
270.	o,p'-DDE	0.02	310.	Prochloraz	0.05
271.	o,p'-DDT	0.02	311.	Procymidone	0.05
272.	Omethoate	0.05	312.	Profenophos	0.05
273.	Oxadiazon	0.05	313.	Promecarb	0.02
274.	Oxadixyl	0.05	314.	Prometryn	0.05
275.	Oxamyl	0.05	315.	Propamocarb hydrochloride	0.05
276.	Oxathiapiprolin	0.05	316.	Propanil	0.05
277.	Oxycarboxin	0.05	317.	Propaphos	0.05
278.	Oxydemeton-methyl	0.05	318.	Propargite	0.05
279.	Oxyfluorfen	0.05	319.	Propazine	0.05
280.	p,p'-DDD	0.02	320.	Propiconazole	0.05

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Appendix

Report No. : AFA23305232M01

Date : 2023/04/12



Test items & LOQ List :

Unit: ppm

No.	Test Item	LOQ	No.	Test Item	LOQ
321.	Propoxur	0.05	361.	Simazine	0.05
322.	Proquinazid	0.05	362.	Spinetoram J	0.05
323.	Prothiofos	0.05	363.	Spinetoram L	
324.	Prothoate	0.05	364.	Spinosyn A	0.05
325.	Pydiflumetofen	0.05	365.	Spinosyn D	
326.	Pyflubumide	0.05	366.	Spirodiclofen	0.05
327.	Pymetrozine	Note 6	367.	Spiromesifen	0.05
328.	Pyracarbolid	0.05	368.	Spirotetramat	0.05
329.	Pyraclufos	0.05	369.	Spiroxamine	0.05
330.	Pyraclostrobin	0.05	370.	Sulfentrazone	0.05
331.	Pyraflufen-ethyl	0.05	371.	Sulfoxaflor	0.05
332.	Pyrazophos	0.05	372.	Tebuconazole	0.05
333.	Pyrazosulfuron-ethyl	0.05	373.	Tebufenozide	0.05
334.	Cinerin I	0.05	374.	Tebufenpyrad	0.05
335.	Cinerin II		375.	Teflubenzuron	0.05
336.	Jasmolin I		376.	Tepaloxymid	0.05
337.	Jasmolin II		377.	Terbufos	0.05
338.	Pyrethrin I		378.	Tetraconazole	0.05
339.	Pyrethrin II		379.	Tetradifon	0.05
340.	Pyribencarb		0.05	380.	Tetramethrin
341.	Pyridaben	0.05	381.	Tetraniliprole	0.05
342.	Pyridaphenthion	0.05	382.	Thenylchlor	0.05
343.	Pyridate	0.05	383.	Thiabendazole	0.05
344.	Pyrifenoxy	0.05	384.	Thiacloprid	0.05
345.	Pyriproxyfen	0.05	385.	Thiamethoxam	0.05
346.	Pyrimethanil	0.05	386.	Thifluzamide	0.05
347.	Pyrimidifen	0.05	387.	Thiobencarb	0.05
348.	Pyriofenone	0.05	388.	Thiodicarb	0.05
349.	Pyriproxyfen	0.05	389.	Thiofanox	0.05
350.	Pyroquilon	0.05	390.	Thiometon	0.05
351.	Quinalphos	0.05	391.	Tolclofos-methyl	0.05
352.	Quinoxifen	0.05	392.	Tolfenpyrad	0.05
353.	Quintozene (PCNB)	0.02	393.	Tolyfluanid	0.05
354.	Quinalofop-ethyl	0.05	394.	trans-Chlordane	0.05
355.	Rotenone	0.05	395.	Triadimefon	0.05
356.	Saflufenacil	0.05	396.	Triadimenol	0.05
357.	Salithion	0.03	397.	Triazophos	0.05
358.	Sedaxane	0.05	398.	Trichlorfon	0.05
359.	Sethoxydim	0.05	399.	Tricyclazole	0.05
360.	Silafluofen	0.05	400.	Tridiphane	0.05

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.



**Appendix**

Report No. : AFA23305232M01

Date : 2023/04/12



**Test items & LOQ List :**

Unit: ppm

No.	Test Item	LOQ	No.	Test Item	LOQ
401.	Trifloxystrobin	0.05	407.	Vamidothion	0.05
402.	Triflumezopyrim	0.05	408.	Vinclozolin	0.05
403.	Triflumizole	0.05	409.	XMC (Macbal)	0.05
404.	Triflumuron	0.05	410.	Zoxamide	0.05
405.	Trifluralin	0.04			
406.	Triforine	0.05			

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Global Eyes Corporation  
1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei  
City, Taiwan

Report No. : AFA23305232M01

Date : 2023/04/12



**Product Name :** coffee Tabs  
**Sample Packaging :** Please refer to the photos for sample shown at the page of this report  
**Sample Condition/Amount :** Ambient temp./5 pieces  
**Item No. :** —  
**Lot. No. :** —  
**Applicant :** Global Eyes Corporation  
**Applicant address/  
telephone number/  
contact person :** 1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei City 241,  
Taiwan/02-22789928/蔡佳勳  
**Manufacturer/Vendor :** Gloabal Eyes Corporation  
**Manufacture Date :** —  
**Expiry Date :** —  
**Country of Origin :** TAIWAN

The above sample information is provided and confirmed by the applicant.

**Sample Received :** 2023/03/17  
**Testing Date :** 2023/03/17  
**Test Results:** -Please refer to next page(s)-

*Gar Sung*  
Gar Sung, Manager  
Signed for and on behalf of  
SGS Taiwan Ltd.



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

**Global Eyes Corporation**  
 1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei  
 City, Taiwan

**Report No. : AFA23305232M01**  
**Date : 2023/04/12**



Test Item	Test Method	Results	LOQ/LOD	Unit
365 Chemicals for clinical use	---	---	---	---
The sample is tested 365 Chemicals for clinical use (see appendix).	According to SGS inhouse method(TESP-UB-0173 , TESP-UB-0181 , TESP-UB-0182) . Analysis was performed by TLC, LC/MS/MS or GC/MS.	N.D.	---	ppm (µg/g)
55 Potent Drugs	---	---	---	---
The sample is tested 55 Potent Drugs (see appendix).	According to SGS inhouse method(TESP-UB-0173 , TESP-UB-0181 , TESP-UB-0182) . Analysis was performed by TLC, LC/MS/MS or GC/MS.	N.D.	---	ppm (µg/g)

NOTE :

- 1.The test report merely reflects the test results of the consigned matters of the client and is not a certification of the legitimacy of the related products.
- 2.This testing report contains 27 pages and it's invalid when they are separated.
- 3.If the testing item belongs to quantitative analysis then this column describes Limit of Quantification(LOQ);  
If the testing item belongs to qualitative analysis then this column describes Limit of Detection(LOD).
- 4.All items in this testing report is based on the request from client and we are responsible for that.
- 5.Result reported as "N.D." or "Negative" denotes value lower than LOQ/LOD.
- 6.This testing item (365 Chemicals for clinical use, 55 Potent Drugs) was performed by SGS Ultra Trace & Industrial Safety (UTIS) Laboratory(CUO23300744M01).
- 7.The report, AFA23305232M01, was reissued on 2023/04/12.

- END -

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Report No. : AFA23305232M01

Date : 2023/04/12



**Appendix**

**365 Chemicals for clinical use test items & LOD list:**

Unit: ppm( $\mu$ g/g)

Test Item	CAS NO.	LOD	Test Item	CAS NO.	LOD
2,4-Dinitrophenol	51-28-5	3600	Benzathine-penicillin	41372-02-5	3300
2-Diphenylmethylpyrrolidine	22348-31-8	900	Benzbromarone	3562-84-3	900
7-keto-Dehydroepiandrosterone	566-19-8	3000	Benzhexol	144-11-6	1800
Acetaminophen	103-90-2	300	Benzocaine	94-09-7	300
Acetil acid	147676-78-6	1500	Benzydamine	642-72-8	348
Acetildenafil	831217-01-7	600	Betamethasone	378-44-9	900
Acetohexamide	968-81-0	750	Betamethasone 21 Acetate	987-24-6	4500
Acetophenetidin	62-44-2	3600	Betamethasone Benzoate	22298-29-9	3225
Acetylvaridenafil	1261351-28-3	600	Betamethasone Dipropionate	5593-20-4	1050
Acrinol	1837-57-6	2832	Betamethasone Valerate	2152-44-5	108
Allopurinol	315-30-0	600	Bezafibrate	41859-67-0	600
Ambroxol	18683-91-5	600	Bisacodyl	603-50-9	600
Aminophylline	317-34-0	4500	Bisoprolol Fumarate	104344-23-2	60
Aminopyrine	58-15-1	900	Bromhexine	3572-43-8	1200
Aminotadalafil	385769-84-6	900	Bromopride	4093-35-0	60
Amitriptyline	549-18-8	750	Brompheniramine	86-22-6	1800
Amlodipine	88150-42-9	300	Bromvalerylurea	496-67-3	1950
Amoxicillin	26787-78-0	4320	Bucetin	1083-57-4	600
Amphetamine	300-62-9	375	Bufexamac	2438-72-4	1650
Ampicillin	69-53-4	2700	Buspirone	36505-84-7	3600
Apomorphine	58-00-4	600	Butropium	107080-63-7	3000
Aspirin	50-78-2	600	Caffeine	58-08-2	600
Astemizole	68844-77-9	150	Camyllofine	54-30-8	3000
Atenolol	29122-68-7	300	Carbamazepine	298-46-4	3600
Atorvastatin	134523-00-5	420	Carbetapentane	77-23-6	150
Atropine	51-55-8	150	Carbimazole	22232-54-8	600
Avanafil	330784-47-9	600	Carbinoxamine	486-16-8	1650
Baclofen	1134-47-0	300	Carbodenafil	944241-52-5	1500
Barbital	57-44-3	750	Carisoprodol	78-44-4	375
Benazepril	86541-75-5	450	Carvedilol	72956-09-3	2400
Benproperine	2156-27-6	600	Cefamandole nafate	42540-40-9	150

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Report No. : AFA23305232M01

Date : 2023/04/12



**Appendix**

**365 Chemicals for clinical use test items & LOD list:**

Unit: ppm(µg/g)

Test Item	CAS NO.	LOD	Test Item	CAS NO.	LOD
Cefazolin	25953-19-9	1050	Cloperastine	3703-76-2	1500
Cefoperazone dihydrate	113826-44-1	300	Clotrimazole	23593-75-1	3000
Cefotaxime	63527-52-6	150	Cloxacillin Sodium	7081-44-9	4770
Ceftriaxone	73384-59-5	4224	Clozapine	5786-21-0	600
Celecoxib	169590-42-5	900	Cocaine	50-36-2	750
Cephalexin	15686-71-2	75	Colchicine	64-86-8	750
Cephradine	38821-53-3	81	Cortisone	53-06-5	750
Cetilistat	282526-98-1	1500	Cortisone acetate	50-04-4	3600
Cetirizine	83881-51-0	159	Cyproheptadine	129-03-3	1500
Chloramphenicol	56-75-7	1200	Desacetyl bisacodyl	603-41-8	600
Chlordiazepoxide	58-25-3	300	Desacetyl diltiazem	42399-40-6	60
Chlorhexidine	55-56-1	2400	Dexamethasone	50-02-2	1200
Chlormezanone	80-77-3	60	Dexamethasone phosphate	312-93-6	900
Chloropretadafil	171489-59-1	1500	Dextromethorphan	125-71-3	1500
Chlorothiazide	58-94-6	750	Diazepam	439-14-5	300
Chlorpheniramine	113-92-8	1200	Dibucaine	85-79-0	450
Chlorpromazine	50-53-3	300	Diclofenac	15307-86-5	600
Chlorpropamide	94-20-2	600	Dicyclomine	77-19-0	375
Chlortetracycline	57-62-5	600	Diethylpropion	39648-50-5	450
Chlorzoxazone	95-25-0	1050	Diethylstilbestrol	56-53-1	600
Cimetidine	51481-61-9	1500	Difloxacin	98106-17-3	3000
Cinnarizine	298-57-7	600	Digitoxin	71-63-6	450
Ciprofloxacin(CFA)	85721-33-1	240	Dihydroergotamine	511-12-6	150
Clenbuterol	21898-19-1	900	Diltiazem	42399-41-7	300
Clindamycin HCl	21462-39-5	456	Dimenhydrinate	523-87-5	150
Clindamycin phosphate	24729-96-2	150	Dimethylsildenafil	496835-35-9	3000
Clobenzorex	13364-32-4	375	Dimetridazole	551-92-8	150
Clobetasol Propionate	25122-46-7	2400	Diphenhydramine	58-73-1	375
Clofibrate	637-07-0	1500	Diphenylhydantoin	57-41-0	150
Clonazepam	1622-61-3	150	Diprophylline	479-18-5	900
Clonidine	4205-90-7	300	Dipyridamole	58-32-2	450

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Report No. : AFA23305232M01

Date : 2023/04/12



**Appendix**

**365 Chemicals for clinical use test items & LOD list:**

Unit: ppm( $\mu$ g/g)

Test Item	CAS NO.	LOD	Test Item	CAS NO.	LOD
Dipyron	68-89-3	600	Fluocinonide	356-12-7	3600
Dithio-desmethyl-carbodenafil	1333233-46-7	1500	Fluoxetine	54910-89-3	1200
Doxazosin	74191-85-8	2400	Fluoxymesterone	76-43-7	600
Doxycycline	564-25-0	576	Flurbiprofen	5104-49-4	150
Doxylamine	469-21-6	60	Fluvastatin	93957-54-1	1200
Dyclonine Hydrochloride	536-43-6	3600	Furosemide	54-31-9	600
Econazole	27220-47-9	150	Gemfibrozil	25812-30-0	4500
Enrofloxacin	93106-60-6	3090	Gendenaflil	147676-66-2	3000
Eprazinone	10402-90-1	300	Glibenclamide	10238-21-8	4800
Erythromycin	114-07-8	240	Glimepiride	93479-97-1	2400
Estazolam	29975-16-4	60	Glipizide	29094-61-9	3000
Estradiol	50-28-2	1200	Glycopyrronium	740028-90-4	900
Estradiol benzoate	50-50-0	600	Griseofulvin	126-07-8	450
Estriol	50-27-1	60	Guaifenesin	93-14-1	2400
Estrone	53-16-7	30	Haloperidol	52-86-8	1620
Ethinyl estradiol	57-63-6	30	Homatropine	87-00-3	150
Ethisterone	434-03-7	600	Homosildenafil	642928-07-2	1350
Ethoxybenzamide	938-73-8	600	Hydralazine	86-54-4	450
Ethylestrenol	965-90-2	30	Hydrochlorothiazide	58-93-5	600
Etodolac	41340-25-4	600	Hydrocortisone	50-23-7	750
Etofibrate	31637-97-5	3000	Hydroxyacetildenafil	147676-56-0	600
Famotidine	76824-35-6	750	Hydroxyhomosildenafil	139755-85-4	1200
Fenbufen	36330-85-5	1875	Hydroxythiohomosildenafil	479073-82-0	1650
Fenfluramine	458-24-2	375	Hydroxyvardenafil	224785-98-2	1500
Fenofibrate	49562-28-9	150	Hydroxyzine	2192-20-3	900
Fenoterol	13392-18-2	750	Ibuprofen	15687-27-1	1200
Finasteride (Proscar)	98319-26-7	3000	Imidazosagatriazinone	139756-21-1	1200
Flavoxate	15301-69-6	900	Imipramine	50-49-7	60
Flibanserin	167933-07-5	3600	Indapamide	26807-65-8	2400
Fluconazole	86386-73-4	480	Indomethacin	53-86-1	1200
Flufenamic acid	530-78-9	4050	Isoniazid	54-85-3	302.4

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Report No. : AFA23305232M01

Date : 2023/04/12



**Appendix**

**365 Chemicals for clinical use test items & LOD list:**

Unit: ppm(µg/g)

Test Item	CAS NO.	LOD	Test Item	CAS NO.	LOD
Ketoconazole	65277-42-1	300	Metronidazole	443-48-1	900
Ketoprofen	22071-15-4	450	Mexiletine	31828-71-4	1500
Ketotifen fumarate	34580-14-8	60	Midazolam	59467-70-8	60
Lidocaine	137-58-6	60	Minocycline	10118-90-8	750
Lincomycin	154-21-2	1710	Minoxidil	38304-91-5	600
Liothyronine	6893-02-3	3600	Morphine	57-27-2	150
Lomefloxacin	98079-51-7	1500	Nalidixic acid	389-08-2	300
Lorazepam	846-49-1	300	Naloxone	465-65-6	384
Lorcaserin	616202-92-7	900	Naltrexone	16590-41-3	2370
Maprotiline	10262-69-8	150	Nandrolone	434-22-0	750
Mazindol	22232-71-9	1950	Naphazoline Hydrochloride	835-31-4	300
Meclizine	569-65-3	60	Naproxen	22204-53-1	900
Mefenamic acid	61-68-7	900	N-Desethylvaridenafil	448184-46-1	3000
Melatonin	73-31-4	1200	N-Desethylacetildenafil	147676-55-9	3000
Meloxicam	71125-38-7	4500	N-Desmethysibutramine	168835-59-4	3000
Meperidine	57-42-1	150	N-Desmethysildenafil	139755-82-1	3000
Mephenesin	59-47-2	150	N-Didesmethysibutramine	84467-54-9	3000
Mephentermine	100-92-5	240	Nefopam	13669-70-0	300
Meprobamate	57-53-4	375	Nicametate	3099-52-3	2550
Metformin	657-24-9	300	Nicotine	54-11-5	60
Methamphetamine	537-46-2	750	Nifedipine	21829-25-4	600
Methandriol	521-10-8	2400	Nifuroxazide	965-52-6	540
Methandrostenolone	72-63-9	600	Nitrazepam	146-22-5	600
Methaqualone	72-44-6	900	Nitrofurantoin	67-20-9	450
Metharbital	50-11-3	750	Nitrofurazone	59-87-0	4410
Methimazole	60-56-0	300	Noracetildenafil	949091-38-7	300
Methyl DOPA-Sesquihydrate	41372-08-1	1620	Noraminopyrine	519-98-2	2400
Methylprednisolone	83-43-2	750	Norethisterone	68-22-4	600
Methyltestosterone	58-18-4	600	Norfloracin	70458-96-7	300
Metoclopramide	364-62-5	750	Norfludiazepam	2886-65-9	150
Metoprolol	51384-51-1	150	Norgestrel	6533-00-2	600

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Report No. : AFA23305232M01

Date : 2023/04/12



**Appendix**

**365 Chemicals for clinical use test items & LOD list:**

Unit: ppm( $\mu$ g/g)

Test Item	CAS NO.	LOD	Test Item	CAS NO.	LOD
Norneosildenafil	371959-09-0	1000	Piperidenafil	224788-34-5	1500
Nortadalafile	171596-36-4	1500	Pirenzepine	28797-61-7	1350
Noscapine	128-62-1	300	Piroxicam	36322-90-4	600
Nylidrin	849-55-8	4500	Prazosin	19216-56-9	300
Ofloxacin	82419-36-1	1920	Prednisolone	50-24-8	1200
Omeprazole	73590-58-6	1200	Prednisone	53-03-2	750
Orlistat	96829-58-2	375	Prilocaine	721-50-6	750
Orphenadrine	83-98-7	300	Primidone	125-33-7	30
Oxeladin	468-61-1	120	Probenecid	57-66-9	900
Oxethazaine	126-27-2	150	Procaine	59-46-1	300
Oxybutynin	5633-20-5	4635	Progesterone	57-83-0	600
Oxymetholone	434-07-1	1050	Promethazine	60-87-7	300
Oxyphenbutazone	129-20-4	450	Propafenone	54063-53-5	2400
Oxyphencylimine	125-53-1	75	Propantheline	298-50-0	3000
Oxytetracycline (OTC)	79-57-2	960	Propranolol	525-66-6	1350
Papaverine	58-74-2	1560	Propyphenazone	479-92-5	3000
Pentazocine	359-83-1	30	Quetiapine	111974-69-7	2400
Pentobarbital	76-74-4	150	Quinine	130-95-0	300
Pentoxifylline	6493-05-6	2400	Ranitidine	66357-59-3	600
Phenacetin	62-44-2	3600	Reserpine	50-55-5	1200
Phenazopyridine	94-78-0	750	Rifampin	13292-46-1	120
Phenformin	114-86-3	900	Rimonabant	168273-06-1	3000
Phenobarbital	50-06-6	900	Rosiglitazone	122320-73-4	3000
Phenolphthalein	77-09-8	600	Salbutamol	18559-94-9	37.5
Phentermine	122-09-8	1500	Salicylamide	65-45-2	600
Phentolamine	50-60-2	1500	Salicylic acid	69-72-7	900
Phenylbutazone	50-33-9	750	Santonin	481-06-1	450
Phenylephrine	59-42-7	2850	Scopolamine	6533-68-2	150
Phenylpropanolamine	14838-15-4	60	Secobarbital	76-73-3	900
Pioglitazone	111025-46-8	1200	Sibutramine	106650-56-0	1200
Piperiacetildenafil	147676-50-4	3000	Sildenafil	139755-83-2	1200

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.



Report No. : AFA23305232M01

Date : 2023/04/12



**Appendix**

**365 Chemicals for clinical use test items & LOD list:**

Unit: ppm( $\mu$ g/g)

Test Item	CAS NO.	LOD	Test Item	CAS NO.	LOD
Simvastatin	79902-63-9	600	Tetracycline	60-54-8	750
Spironolactone	52-01-7	300	Tetramethylpyrazine	1124-11-4	2400
Stanozolol	10418-03-8	2100	Theobromine	83-67-0	600
Strychnine	57-24-9	900	Theophylline	58-55-9	600
Sulfadiazine	68-35-9	600	Thiodimethylsildenafil	856190-47-1	450
Sulfadimethoxine	122-11-2	750	Thiohomosildenafil	479073-80-8	450
Sulfamerazine	127-79-7	450	Thioridazine	50-52-2	300
Sulfamethazine	57-68-1	600	Thiosildenafil	479073-79-5	450
Sulfamethizole	144-82-1	600	Tiletamine	14176-49-9	300
Sulfamethoxazole	723-46-6	600	Timolol Maleate	26921-17-5	150
Sulfamethoxyipyridazine	80-35-3	450	Tinidazole	19387-91-8	900
Sulfamonomethoxine	1220-83-3	4650	Tolbutamide	64-77-7	375
Sulfanilamide	63-74-1	375	Topiramate	97240-79-4	450
Sulfapyridine	144-83-2	2400	Trazodone hydrochloride	19794-93-5	3000
Sulfaquinolaxaline	59-40-5	4740	Triamcinolone	124-94-7	900
Sulfathiazole	72-14-0	600	Triamcinolone acetonide	76-25-5	4800
Sulfipyrazone	57-96-5	750	Triazolam	28911-01-5	150
Sulfisomidine	515-64-0	3000	Trimethoprim	738-70-5	1500
Sulfisoxazole	127-69-5	450	Tripolidine	486-12-4	60
Sulindac	38194-50-2	750	Usnic acid	125-46-2	3600
Sulpiride	15676-16-1	1140	Vardenafil	224785-90-4	1800
Synephrine	94-07-5	450	Desulfovardenafil	224789-21-3	1800
Tadalafil	171596-29-5	600	Verapamil	152-11-4	60
Terbinafine	91161-71-6	300	Xanthinol Niacinate	437-74-1	1050
Terfenadine	50679-08-8	450	Yohimbine	146-48-5	1500
Testosterone	58-22-0	600	Zolazepam HCl	31352-82-6	60
Testosterone propionate	57-85-2	3000	Zolpidem	82626-48-0	300
Tetracaine	94-24-6	600	---	---	---

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Report No. : AFA23305232M01

Date : 2023/04/12



**Appendix**

**55 Potent Drugs Test Items & LOD list:**

Unit: ppm(µg/g)

Test Item	CAS NO.	LOD	Test Item	CAS NO.	LOD
Desulfovardenafil	224789-21-3	1800	Acetylvaridenafil	1261351-28-3	600
7-keto-Dehydroepiandrosterone	566-19-8	3000	N-Butyl Tadalafil(Molecular weight431.50)	171596-31-9	450
Acetil acid	147676-78-6	1500	N-Octylnortadalafil(Molecular weight487.60)	1173706-35-8	30
Acetildenafil	831217-01-7	600	Nortadalafil	171596-36-4	1500
Aminotadalafil	385769-84-6	900	Propoxyphenyl aildenafil(Molecular weight502.64)	1391053-82-9	3000
Carbodenafil	944241-52-5	1500	Dithio-desmethyl-carbodenafil(Molecular weight470.66)	1333233-46-7	1500
Chloropretadalafil	171489-59-1	1500	Desmethyl carbodenafil(Molecular weight438.53)	147676-79-7	2400
N-Desmethysildenafil	139755-82-1	3000	Avanafil	330784-47-9	600
N-Desethylacetildenafil	147676-55-9	3000	Sildenafil analogue(Molecular weight484.68)	2146091-79-2	3000
Dimethylsildenafil	496835-35-9	3000	Propoxyphenyl thioaildenafil(Molecular weight518.70)	856190-49-3	1500
Gendenafil	147676-66-2	3000	Propoxyphenyl thiohydroximosildenafil(Molecular weight534.69)	479073-90-0	2400
Homosildenafil	642928-07-2	1350	Descarbonsildenafil(Molecular weight462.57)	1393816-99-3	2400
Hydroxyacetildenafil	147676-56-0	600	Demethylpiperaziny sildenafil sulfonic acid (Molecular weight392.43)	1357931-55-5	2400
Hydroxyhomosildenafil	139755-85-4	1200	O-Desethyl sildenafil (Molecular weight446.52)	139755-91-2	4500
Hydroxythiosildenafil	479073-82-0	1650	N-Ethyl Tadalafil (Molecular weight403.44)	1609405-34-6	3000
Hydroxyvaridenafil	224785-98-2	1500	Propoxyphenyl sildenafil (Molecular weight488.61)	877777-10-1	3000
Imidazosagatriazinone	139756-21-1	1200	Tadalafil analogue (Molecular weight463.54)	---	2400
N-Desethylvaridenafil	448184-46-1	3000	Propoxyphenyl thiosildenafil (Molecular weight504.68)	479073-87-5	4500
Norneosildenafil	371959-09-0	1000	Propoxyphenyl homohydroxysildenafil(Molecular weight518.63)	139755-87-6	3600
Piperiacetildenafil	147676-50-4	3000	Dithio-Desethyl Carbodenafil (Molecular weight456.64)	1610830-81-3	4800
Piperidenafil	224788-34-5	1500	Tadalafil analogue (Molecular weight435.48)	---	300
Sildenafil	139755-83-2	1200	2-Hydroxyethyl Nortadalafil (Molecular weight419.44)	1639860-36-8	4800
Tadalafil	171596-29-5	600	2-Hydroxypropyl nortadalafil(Molecular weight433.46)	1353020-85-5	2400
Thiodimethylsildenafil	856190-47-1	450	Dipropylaminopretadalafil(Molecular weight491.59)	---	3000
Thiohomosildenafil	479073-80-8	450	Vardenafil analogue(Molecular weight437.54)	---	3600
Thiosildenafil	479073-79-5	450	Desethyl carbodenafil(Molecular weight424.51)	1027192-92-2	3600
Vardenafil	224785-90-4	1800	N-3-hydroxypropylnortadalafil(Molecular weight433.46)	---	3000
Noracetildenafil	949091-38-7	300	---	---	---

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Global Eyes Corporation  
1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New  
Taipei City, Taiwan

Report No. : AFA23305232M01

Date : 2023/04/12



**Product Name :** coffee Tabs  
**Sample Packaging :** Please refer to the photos for sample shown at the page of this report  
**Sample Condition/Amount :** Ambient temp./5 pieces  
**Item No. :** —  
**Lot. No. :** —  
**Applicant :** Global Eyes Corporation  
**Applicant address/  
telephone number/  
contact person :** 1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei City 241,  
Taiwan/02-22789928/蔡佳勳  
**Manufacturer/Vendor :** Gloabal Eyes Corporation  
**Manufacture Date :** —  
**Expiry Date :** —  
**Country of Origin :** TAIWAN

The above sample information is provided and confirmed by the applicant.

**Sample Received :** 2023/03/17  
**Testing Date :** 2023/03/17  
**Test Results:** -Please refer to next page(s)-

*Gar Sung*  
Gar Sung, Manager  
Signed for and on behalf of  
SGS Taiwan Ltd.



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Global Eyes Corporation  
1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei  
City, Taiwan

Report No. : AFA23305232M01

Date : 2023/04/12



Test Item	Test Method	Results	LOQ/LOD (Note 3.)	Unit
Energy	[4*Total Carbohydrate+4*Crude Protein+9*Crude Fat] Kcal	419.4	---	Kcal/100g
⊙ Crude Protein	AOAC 992.15 (1992) Crude Protein in Meat and Meat Products Including Pet Foods	6.7	0.1	g/100g
⊙ Crude Fat	CNS 5036 Methods of Test for Crude Fat in Food.(Date of Revision on 1984/01/14)	8.6	0.1	g/100g
⊙ expressed as sum of saturated fat	MOHW Food No. 1021950978 promulgated on 2013/11/28. Method of Test for Fatty Acids in Food. (MOHWO0014.00)	8.23	0.05	g/100g
⊙ expressed as sum of trans fat	MOHW Food No. 1021950978 promulgated on 2013/11/28. Method of Test for Fatty Acids in Food. (MOHWO0014.00)	N.D.	0.05	g/100g
Total Carbohydrate	100-(Crude Protein + Crude Fat + Moisture + Ash)	78.8	---	g/100g
⊙ Sugars	CNS12634 Method of Test for fruit and vegetable juice products-Determination of sugars by HPLC (Date of Revision on 2006/04/19)	15.4	0.5	g/100g
⊙ Moisture	CNS 5033 Methods of Test for Moisture in Food.(Date of Revision on 1984/01/14)	3.3	0.1	g/100g
⊙ Ash	CNS 5034 Method of Test for Ash in Food.(Date of Revision on 1984/01/14)	2.6	0.1	g/100g
⊙ Dietary Fiber	AOAC 985.29 (1986) Total Dietary Fiber in Foods	5.7	0.5	g/100g
Sodium	AOAC 984.27 (1986) Calcium, Copper, Iron, Magnesium, Manganese, Phosphorus, Potassium, Sodium and Zinc in Infant Formula.	31.1	0.2	mg/100g

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

**Global Eyes Corporation**  
 1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei  
 City, Taiwan

Report No. : AFA23305232M01

Date : 2023/04/12



Test Item	Test Method	Results	LOQ/LOD (Note 3.)	Unit
⊙ Cholesterol	AOAC 994.10(1994) Cholesterol In Foods	N.D.	5	mg/100g
Vitamin D	TFDAA0025.00-Method of Test for Fat-Soluble Vitamins in Foods. (Promulgated, Aug 21.2014). Analysis was performed by HPLC/DAD.	N.D.	0.0005	mg/g
Calcium	AOAC 984.27 (1986) Calcium, Copper, Iron, Magnesium, Manganese, Phosphorus, Potassium, Sodium and Zinc in Infant Formula.	27.7	0.2	mg/100g
Iron		0.8	0.2	mg/100g
Potassium		436.7	0.2	mg/100g

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Global Eyes Corporation  
1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei  
City, Taiwan

Report No. : AFA23305232M01  
Date : 2023/04/12



Test Item	Test Method	Results	LOQ/LOD (Note 3.)	Unit
⊙ Trans Fatty Acid	---	---	---	---
⊙ 9-trans-tetradecenoic acid (9t-14:1)	MOHW Food No. 1021950978 promulgated on 2013/11/28. Method of Test for Fatty Acids in Food. (MOHWO0014.00)	N.D.	0.05	g/100g
⊙ 9-trans-hexadecenoic acid (9t-16:1)		N.D.	0.05	g/100g
⊙ 6-trans-octadecenoic acid (6t-18:1)		N.D.	0.05	g/100g
⊙ 9-trans-octadecenoic acid (9t-18:1)		N.D.	0.05	g/100g
⊙ 11-trans-octadecenoic acid (11t-18:1)		N.D.	0.05	g/100g
⊙ 9,12-trans-octadecadienoic acid (9t,12t-18:2)		N.D.	0.05	g/100g
⊙ 9-cis,12-trans-octadecadienoic acid (9c,12t-18:2)		N.D.	0.05	g/100g
⊙ 9-trans,12-cis-octadecadienoic acid (9t,12c-18:2)		N.D.	0.05	g/100g
⊙ 9,12,15-trans-octadecatrienoic acid (9t,12t,15t-18:3)		N.D.	0.05	g/100g
⊙ 9-trans,12-trans,15-cis-octadecatrienoic acid (9t,12t,15c-18:3)		N.D.	0.05	g/100g
⊙ 9-trans,12-cis,15-trans-octadecatrienoic acid (9t,12c,15t-18:3)		N.D.	0.05	g/100g
⊙ 9-cis,12-trans,15-trans-octadecatrienoic acid (9c,12t,15t-18:3)		N.D.	0.05	g/100g
⊙ 9-cis,12-cis,15-trans-octadecatrienoic acid (9c,12c,15t-18:3)		N.D.	0.05	g/100g
⊙ 9-cis,12-trans,15-cis-octadecatrienoic acid (9c,12t,15c-18:3)		N.D.	0.05	g/100g
⊙ 9-trans,12-cis,15-cis-octadecatrienoic acid (9t,12c,15c-18:3)		N.D.	0.05	g/100g

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Global Eyes Corporation  
1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei  
City, Taiwan

Report No. : AFA23305232M01

Date : 2023/04/12



Test Item	Test Method	Results	LOQ/LOD (Note 3.)	Unit
⊙ Saturated Fatty Acid	---	---	---	---
⊙ tetraoic acid (4:0)	MOHW Food No. 1021950978 promulgated on 2013/11/28. Method of Test for Fatty Acids in Food. (MOHWO0014.00)	N.D.	0.05	g/100g
⊙ hexanoic acid (6:0)		N.D.	0.05	g/100g
⊙ octanoic acid (8:0)		0.43	0.05	g/100g
⊙ decanoic acid (10:0)		0.34	0.05	g/100g
⊙ undecanoic acid (11:0)		N.D.	0.05	g/100g
⊙ dodecanoic acid (12:0)		3.05	0.05	g/100g
⊙ tridecanoic acid (13:0)		N.D.	0.05	g/100g
⊙ tetradecanoic acid (14:0)		1.08	0.05	g/100g
⊙ pentadecanoic acid (15:0)		N.D.	0.05	g/100g
⊙ hexadecanoic acid (16:0)		1.46	0.05	g/100g
⊙ heptadecanoic acid (17:0)		N.D.	0.05	g/100g
⊙ octadecanoic acid (18:0)		1.87	0.05	g/100g
⊙ eicosanoic acid (20:0)		N.D.	0.05	g/100g
⊙ docosanoic acid (22:0)		N.D.	0.05	g/100g
⊙ tricosanoic acid (23:0)		N.D.	0.05	g/100g
⊙ tetracosanoic acid (24:0)		N.D.	0.05	g/100g

NOTE :

- The test report merely reflects the test results of the consigned matters of the client and is not a certification of the legitimacy of the related products.
- This testing report contain 27 pages and it's invalid when they are separated.
- If the testing item belongs to quantitative analysis then this column describes Limit of Quantification(LOQ). If the testing item belongs to qualitative analysis then this column describes Limit of Detection(LOD).
- The testing result will be N.D. or Negative for Limit of Quantification and Limit of Detection, respectively.
- All items in this testing report is based on the request from client and we are responsible for that.
- Density: N/A
- Crude Protein is calculated by nitrogen factor 6.25
- These testing items (Energy, Crude Protein, Crude Fat, Saturated Fatty Acid, Trans Fatty Acid, Total Carbohydrate, Sugars, Moisture, Ash, Density, Sodium, Dietary Fiber, Cholesterol, Calcium, Iron, Potassium) were performed by SGS Food Laboratory-Kaohsiung (AVO23303418), which has been accredited by MOHW marked with ⊙.
- This testing item (Vitamin D) was performed by SGS Ultra Trace & Industrial Safety (UTIS) Laboratory(CUO23300744M01).
- The report, AFA23305232M01, was reissued on 2023/04/12.

- END -

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

Global Eyes Corporation  
1F., No. 12-7, Ln. 609, Sec. 5, Chongxin Rd., Sanchong Dist., New Taipei  
City, Taiwan


Report No. : AFA23305232M01

Date : 2023/04/12



Sample Photo

**AFA23305232**



This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.



The information requested from client is shown as below:

AFA23305232M01

Test Item	Test Method	LOQ/LOD
Energy	[4*Total Carbohydrate+4*Crude Protein+9*Crude Fat] Kcal	Please refer to the result table above
⊙ Crude Protein	AOAC 992.15 (1992) Crude Protein in Meat and Meat Products Including Pet Foods	Please refer to the result table above
⊙ Crude Fat	CNS 5036 Methods of Test for Crude Fat in Food.(Date of Revision on 1984/01/14)	Please refer to the result table above
⊙ Saturated Fatty Acid	MOHW Food No. 1021950978 promulgated on 2013/11/28. Method of Test for Fatty Acids in Food. (MOHWO0014.00)	Please refer to the result table above
⊙ Trans Fatty Acid	MOHW Food No. 1021950978 promulgated on 2013/11/28. Method of Test for Fatty Acids in Food. (MOHWO0014.00)	Please refer to the result table above
Total Carbohydrate	100-(Crude Protein + Crude Fat + Moisture + Ash)	Please refer to the result table above
⊙ Sugars	CNS12634 Method of Test for fruit and vegetable juice products-Determination of sugars by HPLC (Date of Revision on 2006/04/19)	Please refer to the result table above
⊙ Moisture	CNS 5033 Methods of Test for Moisture in Food.(Date of Revision on 1984/01/14)	Please refer to the result table above
⊙ Ash	CNS 5034 Method of Test for Ash in Food.(Date of Revision on 1984/01/14)	Please refer to the result table above
Sodium	AOAC 984.27 (1986) Calcium, Copper, Iron, Magnesium, Manganese, Phosphorus, Potassium, Sodium and Zinc in Infant Formula.	Please refer to the result table above
⊙ Dietary Fiber	AOAC 985.29 (1986) Total Dietary Fiber in Foods	Please refer to the result table above
⊙ Cholesterol	AOAC 994.10(1994) Cholesterol In Foods	Please refer to the result table above

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

The information requested from client is shown as below:

AFA23305232M01

Test Item	Test Method	LOQ/LOD
Calcium	AOAC 984.27 (1986) Calcium, Copper, Iron, Magnesium, Manganese, Phosphorus, Potassium, Sodium and Zinc in Infant Formula.	Please refer to the result table above
Iron	AOAC 984.27 (1986) Calcium, Copper, Iron, Magnesium, Manganese, Phosphorus, Potassium, Sodium and Zinc in Infant Formula.	Please refer to the result table above
Potassium	AOAC 984.27 (1986) Calcium, Copper, Iron, Magnesium, Manganese, Phosphorus, Potassium, Sodium and Zinc in Infant Formula.	Please refer to the result table above
Determination of 410 pesticide residues- Multiresidue Analysis (5)	MOHW Food No. 1111901537 amended on 2022/08/17. Method of Test for Pesticide Residues in Foods- Multiresidue Analysis (5).(MOHWP0055.05)(Note : Matrix of the announced method was extended.)	Please refer to the result table above
Arsenic(As)	MOHW Food No. 1031901169 amended on 2014/08/25. General Method of Test for Heavy Metals.(MOHWH0014.03)	Please refer to the result table above
Lead(Pb)	MOHW Food No. 1031901169 amended on 2014/08/25. General Method of Test for Heavy Metals.(MOHWH0014.03)	Please refer to the result table above
Cadmium(Cd)	MOHW Food No. 1031901169 amended on 2014/08/25. General Method of Test for Heavy Metals.(MOHWH0014.03)	Please refer to the result table above
Mercury(Hg)	MOHW Food No. 1031901169 amended on 2014/08/25. General Method of Test for Heavy Metals.(MOHWH0014.03)	Please refer to the result table above
Copper(Cu)	MOHW Food No. 1031901169 amended on 2014/08/25. General Method of Test for Heavy Metals.(MOHWH0014.03)	Please refer to the result table above

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions>. Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.

The information requested from client is shown as below:

AFA23305232M01

Test Item	Test Method	LOQ/LOD
Aflatoxins	MOHW Food No. 1091901654 amended on 2020/09/02. Method of Test for Mycotoxins in Foods-Test of Aflatoxins.(MOHWT0001.04)(Note : Matrix of the announced method was extended, and it is not within the scope of TFDA certification.)	Please refer to the result table above
365 Chemicals for clinical use	According to SGS inhouse method(TESP-UB-0173 , TESP-UB-0181 , TESP-UB-0182) . Analysis was performed by TLC, LC/MS/MS or GC/MS.	Please refer to the result table above
55 Potent Drugs	According to SGS inhouse method(TESP-UB-0173 , TESP-UB-0181 , TESP-UB-0182) . Analysis was performed by TLC, LC/MS/MS or GC/MS.	Please refer to the result table above
Vitamin D	TFDAA0025.00-Method of Test for Fat-Soluble Vitamins in Foods. (Promulgated, Aug 21.2014). Analysis was performed by HPLC/DAD.	Please refer to the result table above

The testing method has been accredited by MOHW, which is marked with ★.

The externally provided testing method has been accredited by MOHW, which is marked with ®.

This document is issued by the Company subject to its General Conditions of Service printed overleaf, available on request or accessible at <http://www.sgs.com.tw/Terms-and-Conditions> and, for electronic format documents, subject to Terms and Conditions for Electronic Documents at <http://www.sgs.com.tw/Terms-and-Conditions> Attention is drawn to the limitation of liability, indemnification and jurisdiction issues defined therein. Any holder of this document is advised that information contained hereon reflects the Company's findings at the time of its intervention only and within the limits of client's instruction, if any. The Company's sole responsibility is to its Client and this document does not exonerate parties to a transaction from exercising all their rights and obligations under the transaction documents. This document cannot be reproduced, except in full, without prior written approval of the Company. Any unauthorized alteration, forgery or falsification of the content or appearance of this document is unlawful and offenders may be prosecuted to the fullest extent of the law. Unless otherwise stated the results shown in this test report refer only to the sample(s) tested.